Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines.
Enteropathogenic and enterohemorrhagic Escherichia coli are important causal agents of infectious diarrhea, particularly amongst pediatric populations. While enteropathogenic E. coli is a significant health threat in developing countries, enterohemorrhagic E. coli causes sporadic, sometimes deadly outbreaks of hemorrhagic colitis, with a serious complication, hemolytic uremic syndrome, ocurring in a proportion of cases. This review discusses the pathogenesis of enterohemorrhagic and enteropathogenic E. coli, the host immune response and the current application of this knowledge towards efficacious vaccine strategies. Several lines of investigation indicate the feasibility of such strategies and justify further development of a vaccine targeting these significant intestinal pathogens.
Horne
Cathy
C
Biochemistry Labouratory, University of British Columbia, Vancouver, BC, Canada. chorne@interchange.ubc.ca
Vallance
Bruce A
BA
Deng
Wanyin
W
Finlay
B Brett
BB
D000818:Animals; D004927:Escherichia coli Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D019453:Escherichia coli O157 / Q000276:immunology*; D022361:Escherichia coli Vaccines / Q000276:immunology*; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology
D022361:Escherichia coli Vaccines; D008070:Lipopolysaccharides